IDH mutations as an early and consistent marker in low-grade astrocytomas WHO grade II and their consecutive secondary high-grade gliomas. (Q48618352)

13 February 2018

title

IDH mutations as an early and consistent marker in low-grade astrocytomas WHO grade II and their consecutive secondary high-grade gliomas. (English)

1 reference

13 February 2018

4

Silke Soucek

1 reference

13 February 2018

Tareq A Juratli

1

1 reference

13 February 2018

Matthias Kirsch

2

1 reference

13 February 2018

Katja Robel

3

1 reference

13 February 2018

Kathrin Geiger

5

1 reference

13 February 2018

Rüdiger von Kummer

6

1 reference

13 February 2018

Gabriele Schackert

7

1 reference

13 February 2018

Dietmar Krex

8

1 reference

13 February 2018

publication date

13 March 2012

1 reference

13 February 2018

Journal of Neuro-Oncology

published in

1 reference

13 February 2018

volume

108

1 reference

13 February 2018

issue

3

1 reference

13 February 2018

page(s)

403-410

1 reference

13 February 2018

https://scigraph.springernature.com/pub.10.1007/s11060-012-0844-1

exact match

0 references

cites work

An integrated genomic analysis of human glioblastoma multiforme

1 reference

https://api.crossref.org/works/10.1007%2FS11060-012-0844-1

IDH1 and IDH2 mutations in gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-012-0844-1

Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-012-0844-1

Isocitrate dehydrogenase-1 mutations: a fundamentally new understanding of diffuse glioma?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-012-0844-1

Molecular predictors of progression-free and overall survival in patients with newly diagnosed glioblastoma: a prospective translational study of the German Glioma Network

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-012-0844-1

NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine, and vincristine or temozolomide

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-012-0844-1

IDH1 and IDH2 mutations are prognostic but not predictive for outcome in anaplastic oligodendroglial tumors: a report of the European Organization for Research and Treatment of Cancer Brain Tumor Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-012-0844-1

Molecular classification of low-grade diffuse gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-012-0844-1

Isocitrate dehydrogenase 1 codon 132 mutation is an important prognostic biomarker in gliomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-012-0844-1

Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-012-0844-1

DNA methylation, isocitrate dehydrogenase mutation, and survival in glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-012-0844-1

IDH1 mutations in grade II astrocytomas are associated with unfavorable progression-free survival and prolonged postrecurrence survival.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-012-0844-1

Operative techniques for gliomas and the value of extent of resection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-012-0844-1

Randomized trial on the efficacy of radiotherapy for cerebral low-grade glioma in the adult: European Organization for Research and Treatment of Cancer Study 22845 with the Medical Research Council study BRO4: an interim analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-012-0844-1

Molecular markers in low-grade gliomas: predictive or prognostic?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-012-0844-1

Promoter methylation of the DNA repair gene MGMT in astrocytomas is frequently associated with G:C --> A:T mutations of the TP53 tumor suppressor gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-012-0844-1

Aberrant hypermethylation of p14ARF and O6-methylguanine-DNA methyltransferase genes in astrocytoma progression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-012-0844-1

MGMT promoter hypermethylation is a frequent, early, and consistent event in astrocytoma progression, and not correlated with TP53 mutation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-012-0844-1

Long-term efficacy of early versus delayed radiotherapy for low-grade astrocytoma and oligodendroglioma in adults: the EORTC 22845 randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-012-0844-1

Low-grade gliomas in older patients: long-term follow-up from Mayo Clinic

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-012-0844-1

IDH1 or IDH2 mutations predict longer survival and response to temozolomide in low-grade gliomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-012-0844-1

Role of extent of resection in the long-term outcome of low-grade hemispheric gliomas

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/22410704

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1007/S11060-012-0844-1

1 reference

13 February 2018

1 reference

13 February 2018